Latham Advises on CVC’s Sale of Theramex to PAI Partners and Carlyle

Latham & Watkins has advised CVC Capital Partners and Theramex, the leading global specialty pharmaceuticals company focused on women’s health, on the sale of Theramex to global investment firms PAI Partners and Carlyle. The acquisition aims to accelerate the global expansion of Theramex’s diverse suite of products across existing and adjacent therapeutic areas.

Latham previously advised CVC Capital Partners on the formation of the Theramex Group in 2018. Theramex has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health. The company provides patient-focused solutions across contraception, fertility, menopause, and osteoporosis with the aim of providing patients with products that can support them through their life journey.

The Latham team was led by London corporate partners Robbie McLaren and Linzi Thomas, with associates Jon Fox, Katie Peek, Andria Varnavides, and Ismay Brayne. Advice was also provided on regulatory matters by Paris partner Eveline Van Keymeulen, with associate Jeanne Fabre; on data and technology transactions matters by London partner Gail Crawford, with New York counsel Eliot Choy, and London associates Mihail Krepchev and Lorenzo Meusburger; and on finance matters by London partner Fergus O’Domhnaill, with associate Robert Lowe.